Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
11.01
+0.21 (1.94%)
Sep 18, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Market Cap
Lyell Immunopharma has a market cap or net worth of $269.8 million as of September 18, 2026. Its market cap has increased by 14.09% in one year.
Market Cap
269.80M
Enterprise Value
88.40M
1-Year Change
14.09%
Ranking
Category
Stock Price
$11.01
ChartMarket Cap Chart
Since the IPO on June 17, 2021, Lyell Immunopharma's market cap has decreased from $4.13B to $269.80M, a decrease of -93.46%. That is a compound annual growth rate of -40.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 18, 2026 | 269.80M | -58.74% |
| Dec 31, 2025 | 653.89M | 249.70% |
| Dec 31, 2024 | 186.98M | -61.73% |
| Dec 29, 2023 | 488.63M | -43.52% |
| Dec 30, 2022 | 865.16M | -53.52% |
| Dec 31, 2021 | 1.86B | -54.91% |
| Jun 17, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Greenwich LifeSciences | 278.74M |
| Pyxis Oncology | 277.75M |
| Palisade Bio | 277.09M |
| Yarrow Bioscience | 272.52M |
| Sionna Therapeutics | 269.47M |
| Cue Biopharma | 269.15M |
| Camp4 Therapeutics | 266.07M |
| MacroGenics | 263.72M |